Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)
Case Reports
Section edited by Alfred Zippelius, MD
Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach.
- CASE REPORT
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence ...Journal for ImmunoTherapy of Cancer 2017 5:40Published on: 16 May 2017 - CASE REPORT
Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone
Myelophthisis due to melanoma is a rare phenomenon. Treatment strategies for patients with this serious complication of malignancy have not been well documented, and none have previously reported efficacy of i...Journal for ImmunoTherapy of Cancer 2017 5:34Published on: 18 April 2017 - CASE REPORT
Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
Prostate cancer is one of the most common cancers in men and the fourth leading cause of cancer mortality worldwide. Although major progress has been achieved in the last years for patients with metastatic cas...Journal for ImmunoTherapy of Cancer 2017 5:31Published on: 18 April 2017 - CASE REPORT
Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)
CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor clinically targeted for use in cancer treatment. It is expressed exclusively on T-cells where its primary role is t...Journal for ImmunoTherapy of Cancer 2017 5:19Published on: 21 March 2017 - CASE REPORT
Immunotherapy-associated autoimmune hemolytic anemia
Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-...Journal for ImmunoTherapy of Cancer 2017 5:15Published on: 21 February 2017 - CASE REPORT
Nivolumab induced myxedema crisis
Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed...Journal for ImmunoTherapy of Cancer 2017 5:13Published on: 21 February 2017 - CASE REPORT
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation and checkpoint blockade therapy are immune-based therapies that have activity in selected refractory hematologic malignancies. Interest has developed in combi...Journal for ImmunoTherapy of Cancer 2017 5:11Published on: 21 February 2017 - CASE REPORT
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-...Journal for ImmunoTherapy of Cancer 2017 5:8Published on: 21 February 2017 - CASE REPORT
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by thes...Journal for ImmunoTherapy of Cancer 2017 5:3Published on: 17 January 2017 - CASE REPORT
Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
We report a case of sarcoidosis in a patient with metastatic melanoma managed with combination ipilimumab/nivolumab. Sarcoid development has been linked with single agent immunotherapy but, to our knowledge, i...Journal for ImmunoTherapy of Cancer 2016 4:94Published on: 20 December 2016 - CASE REPORT
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
Checkpoint inhibitor immunotherapy is becoming an effective treatment modality for an increasing number of malignancies. As a result, autoinflammatory side-effects are also being observed more commonly in the ...Journal for ImmunoTherapy of Cancer 2016 4:89Published on: 20 December 2016 - CASE REPORT
Metastatic Merkel cell carcinoma response to nivolumab
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with limited treatment options. Several lines of evidence support the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) ...Journal for ImmunoTherapy of Cancer 2016 4:79Published on: 15 November 2016 - CASE REPORT
PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report
Immunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC). The use...Journal for ImmunoTherapy of Cancer 2016 4:83Published on: 15 November 2016 - CASE REPORT
Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy– a report of two cases
Checkpoint inhibitors are a class of agents that employ host’s adaptive immune defenses in fighting cancer. With many new indications and several ongoing clinical trials in a variety of malignancies, the usage...Journal for ImmunoTherapy of Cancer 2016 4:80Published on: 15 November 2016 - CASE REPORT
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) share exposure to UV light as the dominant risk factor, and these tumors therefore harbor high mutation burdens. In other malignancies, h...Journal for ImmunoTherapy of Cancer 2016 4:70Published on: 15 November 2016 - CASE REPORT
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
Nivolumab (Opdivo™) is a novel IgG4 subclass programmed death-1 (PD-1) inhibiting antibody that has demonstrated breakthrough-designation anti-tumor activity. To date, clinical trials of nivolumab and other ch...Journal for ImmunoTherapy of Cancer 2016 4:64Published on: 18 October 2016 - CASE REPORT
Urothelial carcinoma of donor origin in a kidney transplant patient
Malignancy after transplantation is an uncommon multifactorial occurrence. Immunosuppression to prevent graft rejection is described as a major risk factor in malignancy development in the post-transplant stat...Journal for ImmunoTherapy of Cancer 2016 4:63Published on: 18 October 2016 - CASE REPORT
Acute visual loss after ipilimumab treatment for metastatic melanoma
Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related ...Journal for ImmunoTherapy of Cancer 2016 4:66Published on: 18 October 2016 - CASE REPORT
Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade
Antibodies against programmed death 1 (PD-1) receptor and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have transformed the systemic treatment of melanoma and many other cancers. Understanding the spec...Journal for ImmunoTherapy of Cancer 2016 4:58Published on: 20 September 2016 - CASE REPORT
A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover’s disease is an uncommon dermatologic condition with unclear patho...Journal for ImmunoTherapy of Cancer 2016 4:55Published on: 20 September 2016
.png)
No hay comentarios:
Publicar un comentario